Is there a better way to manage obesity than GLP-1 drugs like Ozempic?
In this episode of Oxford+, host Susannah de Jager speaks with Camilla Easter, CEO of Oxford Medical Products, about Sirona—a pioneering, non-pharmaceutical pill that mimics the effects of bariatric surgery without the side effects. Designed to expand in the stomach and promote satiety, Sirona could become the go-to solution for long-term weight loss and maintenance.
Camilla shares the company’s unconventional startup journey, why they avoided the university spinout route, and how the product is positioned to address global obesity, especially among people who can’t access or tolerate drugs like Ozempic or Wegovy. From the challenges of raising capital in a volatile market to clinical trials and FDA approvals, this episode delivers a rich, inspiring look into medtech innovation with wide-reaching health implications.
Camilla Easter: CEO of Oxford Medical Products, Camilla leads the development of Sirona, a pioneering hydrogel-based pill for weight loss and maintenance. With a background in veterinary medicine and startup leadership, she brings scientific insight and entrepreneurial drive to solving complex health problems.
Connect with Camilla on LinkedIn
Susannah de Jager: Susannah is a seasoned professional with over 15 years of experience in UK asset management. She has worked closely with industry experts, entrepreneurs, and government officials to shape the conversation around domestic scale-up capital.
Connect with Susannah on LinkedIn / Subscribe to the Oxford+ Newsletter for exclusive content
Oxford+ is hosted by Susannah de Jager and supported by Mishcon de Reya and Oxford North.
Produced and edited by Story Ninety-Four in Oxford.
